PHARMACEUTICAL COMPOSITION
The present invention provides a novel technology useful for a cancer vaccine therapy, that is, a pharmaceutical composition wherein a Toll-like receptor agonist, LAG-3 protein, a variant thereof or a derivative thereof, at least one immunogenic agent, and an immune checkpoint inhibitor are administered in combination.
1 .- 17 . (canceled)
18 . A method for treating or preventing cancer in a subject comprising administering to the subject,
a Toll-like receptor agonist,
a LAG-3 protein, a variant thereof or a derivative thereof,
at least one immunogenic agent, and
an immune checkpoint inhibitor, in combination.
19 . The method according to claim 18 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody or an anti-CTLA-4 antibody.
20 . The method according to claim 19 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
21 . The method according to claim 18 , wherein the Toll-like receptor agonist is a Toll-like receptor 3 agonist or a Toll-like receptor 9 agonist.
22 . The method according to claim 21 , wherein the Toll-like receptor agonist is Poly I:C or a salt thereof.
23 . The method according to claim 22 , wherein the Poly I:C is Poly ICLC.
24 . The method according to claim 18 , wherein the LAG-3 protein, a variant thereof or a derivative thereof is a fusion protein of LAG-3 protein and IgG.
25 . The method according to claim 18 , wherein the at least one immunogenic agent is at least one cancer antigen-derived peptide.
26 . The method according to claim 25 , wherein the at least one cancer antigen-derived peptide is an HSP70-derived peptide or a GPC3-derived peptide.
27 . The method according to claim 26 , wherein the HSP70-derived peptide consists of the amino acid sequence represented by SEQ ID NO: 7, and the GPC3-derived peptide consists of the amino acid sequence represented by SEQ ID NO: 16.
28 . The method according to claim 18 , wherein
at least one of the Toll-like receptor agonist,
the LAG-3 protein, a variant thereof or a derivative thereof,
the at least one immunogenic agent, and
the immune checkpoint inhibitor
is contained as an active ingredient in a different preparation from a preparation containing at least one of the others, and the preparations are administered at the same time or different times, or
the Toll-like receptor agonist,
the LAG-3 protein, a variant thereof or a derivative thereof,
the at least one immunogenic agent, and
the immune checkpoint inhibitor
are contained as active ingredients in a single preparation and administered.
29 . The method according to claim 18 , being a cancer vaccine therapy.
30 . The method according to claim 18 , wherein the cancer is less sensitive or resistant to the immune checkpoint inhibitor.
31 . A pharmaceutical composition wherein
a Toll-like receptor agonist,
LAG-3 protein, a variant thereof or a derivative thereof,
at least one immunogenic agent, and
an immune checkpoint inhibitor
are administered in combination.
32 . A pharmaceutical composition wherein
a Toll-like receptor agonist,
LAG-3 protein, a variant thereof or a derivative thereof, and
an immune checkpoint inhibitor
are administered in combination.
33 . The pharmaceutical composition according to claim 32 , which is administered further in combination with at least one immunogenic agent.